Applied Biosystems, a division of Life Technologies
(NASDAQ:LIFE), and its mass spectrometry joint-venture partner, MDS
Analytical Technologies, a business unit of MDS Inc. (TSX:MDS)
(NYSE:MDZ), today introduced the AB SCIEX TOF/TOF� 5800 System, the
fastest, most sensitive MALDI-based mass spectrometer ever built.
This system, which is now commercially available, will help
researchers advance the discovery of biomarkers to improve the
understanding of diseases for potential use in a clinical setting,
which is part of the promise of personalized medicine.
The AB SCIEX 5800 System represents a significant advancement in
MALDI-TOF mass spectrometry (matrix-assisted laser
desorption/ionization time-of-flight technology), which works by
ionizing complex biological samples and identifying the individual
protein components by their molecular weight. This system enables
researchers to identify up to 30% more proteins at a rate that is
10 times faster than any other MALDI system on the market, thereby
setting the highest standard for protein biomarker discovery, MALDI
imaging and protein identification. This system, combined with the
release of a new processing software application, ProteinPilot�
3.0, is part of a complete workflow that accelerates proteomics
research.
By expanding the boundaries of protein discovery, the AB SCIEX
5800 System enables scientists to achieve in less than a day what
takes more than two weeks on other MALDI-based systems. This system
is expected to advance the discovery of new biomarkers that could
potentially yield more accurate and sensitive clinical tests in the
future, which is a high priority in the medical and scientific
communities. The AB SCIEX 5800 System enables the discovery of a
wider range of protein biomarkers, enabling scientists to identify
and quantify more proteins in complex samples faster than existing
systems today.
Laura Lauman, President of Life Technologies Mass
Spectrometry Systems Division
�The ability to better understand diseases at the protein level
will ultimately improve diagnosis and help to create more effective
treatments based on an individual�s expression of specific proteins
that relate to a disease or a response to targeted therapies. The
AB SCIEX 5800 System delivers innovative, breakthrough technology
that provides a giant technological leap forward that will help
translate today's biomarker research into tomorrow's personalized
medicine.�
Andy Boorn, President of MDS Analytical Technologies
�We have developed the most advanced MALDI mass spectrometer
ever built. The AB SCIEX 5800 System is another example of how
Applied Biosystems/MDS Analytical Technologies continues to
innovate and develop best-in-class instrument systems that form the
backbone for complete workflow solutions for biomarker and protein
research. This is essential technology for researchers to expand
their protein studies.�
Mark Stolowitz, Ph.D., Director of the Proteomics Core
Facility at the Canary Center for the Early Detection of Cancer at
Stanford University�s School of Medicine
�Mass spectrometry will play a significant role in our efforts
at our new center for cancer research in discovery and verification
of protein biomarkers, contributing to the realization of
personalized medicine, which is closer than many people may think.
We chose the AB SCIEX 5800 System as our facility�s first
proteomics platform because it enables the breadth of applications
we need to hit the ground running. We will use its unique
capabilities to address the gap between biomarker discovery and
clinical immunoassay to ultimately impact patient care.�
Additional Resources
Video: Introduction of the AB SCIEX 5800 System
Technical details: More information about the AB SCIEX 5800
System
ProteinPilot 3.0 Software: Details of processing application for
protein identification and quantitation
Ask the Scientist: Additional information about proteomics
workflows & applications
Background: The role of proteomics in personalized medicine
Applied Biosystems/MDS Analytical Technologies Leadership in
Mass Spectrometry
Applied Biosystems is a global leader in providing innovative
instrument systems to accelerate academic and clinical research,
drug discovery and development, pathogen detection and forensic DNA
analysis. It is a leading provider of mass spectrometry solutions
through its joint venture with MDS Analytical Technologies. Applied
Biosystems, along with Invitrogen � a leading provider of platform
independent, essential life science technologies for disease and
drug research, bioproduction and diagnostics � is part of Life
Technologies. Applied Biosystems and Invitrogen products are used
in nearly every major laboratory in the world.
For more information, please visit: www.appliedbiosystems.com
and www.invitrogen.com.
About Life Technologies
Life Technologies Corporation (NASDAQ:LIFE) is a global
biotechnology tools company dedicated to improving the human
condition. Our systems, consumables and services enable researchers
to accelerate scientific exploration, driving to discoveries and
developments that make life even better. Life Technologies
customers do their work across the biological spectrum, working to
advance personalized medicine, regenerative science, molecular
diagnostics, agricultural and environmental research, and 21st
century forensics. Life Technologies had sales of more than $3
billion in 2008, employs approximately 9,500 people, has a presence
in more than 100 countries, and possesses a rapidly growing
intellectual property estate of approximately 3,600 patents and
exclusive licenses. Life Technologies was created by the
combination of Invitrogen Corporation and Applied Biosystems Inc.
For more information on how we are making a difference please visit
our website: www.lifetechnologies.com.
About MDS Analytical Technologies
MDS Analytical Technologies, a business unit of MDS Inc.
(TSX:MDS) (NYSE:MDZ), is focused on the research, design,
manufacture and marketing of state-of-the-art tools for
mass-spectrometry, drug discovery and bioresearch. MDS Analytical
Technologies� products are designed to help accelerate the complex
process of discovering and developing new drug compounds, and are
sold to research scientists around the world. The mass-spectrometer
product lines are also sold globally through joint ventures with
two of the world�s leading analytical instrumentation and
life-sciences companies, Life Technologies Corporation and
PerkinElmer, Inc. Find out more at www.mdssciex.com or
www.moleculardevices.com.
Life Technologies� Safe Harbor Statement
This press release includes forward-looking statements about our
anticipated results that involve risks and uncertainties. Some of
the information contained in this press release, including, but not
limited to, statements as to industry trends and Life Technologies�
plans, objectives, expectations and strategy for its business,
contains forward-looking statements that are subject to risks and
uncertainties that could cause actual results or events to differ
materially from those expressed or implied by such forward-looking
statements. Any statements that are not statements of historical
fact are forward-looking statements. When used, the words
�believe,� �plan,� �intend,� �anticipate,� �target,� �estimate,�
�expect� and the like, and/or future tense or conditional
constructions (�will,� �may,� �could,� �should,� etc.), or similar
expressions, identify certain of these forward-looking statements.
Important factors which could cause actual results to differ
materially from those in the forward-looking statements are
detailed in filings made by�Life Technologies with the Securities
and Exchange Commission.�Life Technologies undertakes no obligation
to update or revise any such forward-looking statements to reflect
subsequent events or circumstances.
Copyright 2009. Life Technologies Corporation. All rights
reserved. AB SCIEX 5800 TOF/TOF and ProteinPilot are trademarks of
Applied Biosystems/MDS Analytical Technologies, a joint venture
between Life Technologies and MDS Inc.
Photos/Multimedia�Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5934656&lang=en
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Lug 2023 a Lug 2024
